Novo Nordisk A/S Stock

Novo Nordisk A/S Revenue

Revenue

299.23 BDKK

Ticker

NOVO B.CO

ISIN

DK0062498333

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

In 2026, Novo Nordisk A/S's sales reached 299.23 B DKK, a -3.18% difference from the 309.06 B DKK sales recorded in the previous year.

The Novo Nordisk A/S Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B DKK)
GROSS MARGIN (%)
Date
REVENUE (B DKK)
GROSS MARGIN (%)
Jan 1, 2006
38.74
7,526
Jan 1, 2007
41.83
7,659
Jan 1, 2008
45.55
7,781
Jan 1, 2009
51.08
7,956
Jan 1, 2010
60.78
8,078
Jan 1, 2011
66.35
8,103
Jan 1, 2012
78.03
8,274
Jan 1, 2013
83.57
8,308
Jan 1, 2014
88.81
8,360
Jan 1, 2015
107.93
8,500
Jan 1, 2016
111.78
8,463
Jan 1, 2017
111.7
8,421
Jan 1, 2018
111.83
8,425
Jan 1, 2019
122.02
8,397
Jan 1, 2020
126.95
8,351
YEARREVENUE (B DKK)GROSS MARGIN (%)
2031 est 386.0564,83
2030 est 371.2567,41
2029 est 352.0771,09
2028 est 333.8774,96
2027 est 312.3780,12
2026 est 299.2383,64
2025 309.0680,98
2024 290.485,00
2023 232.2684,60
2022 176.9583,92
2021 140.883,20
2020 126.9583,51
2019 122.0283,97
2018 111.8384,25
2017 111.784,21
2016 111.7884,63
2015 107.9385,00
2014 88.8183,60
2013 83.5783,08
2012 78.0382,74
2011 66.3581,03
2010 60.7880,78
2009 51.0879,56
2008 45.5577,81
2007 41.8376,59
2006 38.7475,26

Novo Nordisk A/S Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
38.74 B DKK
9.12 B DKK
6.45 B DKK
Jan 1, 2007
41.83 B DKK
8.94 B DKK
8.52 B DKK
Jan 1, 2008
45.55 B DKK
12.37 B DKK
9.65 B DKK
Jan 1, 2009
51.08 B DKK
14.93 B DKK
10.77 B DKK
Jan 1, 2010
60.78 B DKK
18.89 B DKK
14.4 B DKK
Jan 1, 2011
66.35 B DKK
22.37 B DKK
17.1 B DKK
Jan 1, 2012
78.03 B DKK
29.47 B DKK
21.43 B DKK
Jan 1, 2013
83.57 B DKK
31.64 B DKK
25.18 B DKK
Jan 1, 2014
88.81 B DKK
35.13 B DKK
26.48 B DKK
Jan 1, 2015
107.93 B DKK
46.96 B DKK
34.86 B DKK
Jan 1, 2016
111.78 B DKK
48.97 B DKK
37.93 B DKK
Jan 1, 2017
111.7 B DKK
49.28 B DKK
38.13 B DKK
Jan 1, 2018
111.83 B DKK
47.24 B DKK
38.63 B DKK
Jan 1, 2019
122.02 B DKK
53.68 B DKK
38.95 B DKK
Jan 1, 2020
126.95 B DKK
54.6 B DKK
42.14 B DKK

Novo Nordisk A/S stock margins

The Novo Nordisk A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novo Nordisk A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novo Nordisk A/S.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
75.26 %
23.54 %
16.65 %
Jan 1, 2007
76.59 %
21.38 %
20.37 %
Jan 1, 2008
77.81 %
27.16 %
21.17 %
Jan 1, 2009
79.56 %
29.24 %
21.08 %
Jan 1, 2010
80.78 %
31.08 %
23.7 %
Jan 1, 2011
81.03 %
33.72 %
25.77 %
Jan 1, 2012
82.74 %
37.77 %
27.47 %
Jan 1, 2013
83.08 %
37.86 %
30.13 %
Jan 1, 2014
83.6 %
39.56 %
29.82 %
Jan 1, 2015
85 %
43.51 %
32.3 %
Jan 1, 2016
84.63 %
43.81 %
33.93 %
Jan 1, 2017
84.21 %
44.12 %
34.14 %
Jan 1, 2018
84.25 %
42.24 %
34.54 %
Jan 1, 2019
83.97 %
43.99 %
31.92 %
Jan 1, 2020
83.51 %
43.01 %
33.19 %

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do? Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Novo Nordisk A/S's Sales Figures

The sales figures of Novo Nordisk A/S originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Novo Nordisk A/S’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Novo Nordisk A/S's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Novo Nordisk A/S’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Novo Nordisk A/S stock

Novo Nordisk A/S has achieved a revenue of 299.23 B DKK this year.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: ING and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.